HitGen Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chengdu China (2012)

Organization Overview

First Clinical Trial
2018
NCT03710915
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HitGen Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: HitGen Inc. (0) Acquired (1)

frovatriptan (frova) (2 trials)

Drugs in Phase 2 Trials (6)

Key: HitGen Inc. (0) Acquired (6)

entacapone (comtan) (1 trial)

indantadol (3 trials)

melevodopa (1 trial)

v10153 (1 trial)

v158866 (2 trials)

v81444 (3 trials)

Drugs in Phase 1 Trials (3)

Key: HitGen Inc. (2) Acquired (1)

hg146 (2 trials)

hg381 (1 trial)

v24343 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 16
  • # of Trial APIs: 10